Central Nervous System News and Research

RSS

SMT announces $10.5 million financing to develop novel device for use in TAVI procedures

SMT Research and Development Ltd. of Herzliya Pituach, Israel announced today a significant investment by OrbiMed Advisors LLC. SMT is finalizing the development of a novel embolic protection device designed for use during Transcatheter Aortic Valve Implantation procedures.

4 Apr 2011

ACADIA extends collaboration agreement with Allergan for drug discovery platform

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has extended its drug discovery and development collaboration with Allergan, Inc.

1 Apr 2011

Researchers study role of acetylation in Alzheimer's disease

Researchers at the University of Pennsylvania School of Medicine have determined that a well-known chemical process called acetylation has a previously unrecognized association with one of the biological processes associated with Alzheimer's disease and related disorders. The findings were published in the latest issue of Nature Communications.

1 Apr 2011

Invida, Roche partner to commercialize primary care products

Invida Group Pte Ltd, the leading specialty pharmaceutical company focused on the commercialization of healthcare products throughout Asia Pacific, today announced that it has entered into a partnership agreement with Roche for the commercialization and marketing of that company's primary care portfolio throughout Korea.

1 Apr 2011

Omeros announces outcome from OMS103HP Phase 3 study in patients undergoing ACL surgery

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today reported the outcome from its Phase 3 program evaluating OMS103HP in patients undergoing arthroscopic anterior cruciate ligament reconstruction surgery.

1 Apr 2011

Sleep apnea along with excessive daytime sleepiness elevates risk of death in older adults

A study in the April 1 issue of the journal SLEEP suggests that the risk of death is more than two times higher in older adults who have sleep apnea and report struggling with excessive daytime sleepiness.

1 Apr 2011

New research sheds light on Sudden Infant Death Syndrome

New research published today in The Journal of Physiology sheds light on areas of the brain thought to be the root cause of Sudden Infant Death Syndrome - the poorly understood condition also known as 'cot death'.

1 Apr 2011

AAN honors Mayo Clinic researcher with John Dystel Prize for MS work

The American Academy of Neurology is awarding the 2011 John Dystel Prize for Multiple Sclerosis Research to Brian G. Weinshenker, MD, of the Mayo Clinic in Rochester, Minnesota and a Fellow with the AAN.

1 Apr 2011

Vanda to initiate tasimelteon Phase IIb/III clinical trial in Major Depressive Disorder

Vanda Pharmaceuticals Inc. today announced its plans to initiate a Phase IIb/III clinical trial of tasimelteon in patients with Major Depressive Disorder (MDD). The trial is expected to begin during the second half of 2011. Tasimelteon is currently being evaluated in Phase III clinical trials for the treatment of Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind individuals without light perception.

31 Mar 2011

Adeona reports $3,164,512 net revenue for 2010

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, reported its financial results for the year ended December 31, 2010, as well as updates since the beginning of the 4th quarter.

31 Mar 2011

Rexahn's RX-5902 pre-clinical data against cancer to be presented at AACR Annual Meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present new pre-clinical data on its oncology compound RX-5902 during a poster session at the American Association for Cancer Research 102nd Annual Meeting being held in Orlando, Florida, April 2-6, 2011, at the Orange County Convention Center.

31 Mar 2011

Tips on neurobiology of learning

Everyone would like MDs to have the best education - and to absorb what they are taught. The lead article in the April 4 issue of the journal Academic Medicine connects research on how the brain learns to how to incorporate this understanding into real world education, particularly the education of doctors.

31 Mar 2011

Atypical antipsychotics is a safe mental health medication for nursing home residents

Conventional antipsychotics, antidepressants and benzodiazepines often administered to nursing home residents are no safer than atypical antipsychotics and may carry increased risks, according to an article in CMAJ.

29 Mar 2011

NMSS grants Adeona's ongoing Trimesta trial with $409,426 to treat MS

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that the ongoing clinical trial of its Trimesta drug candidate has received an additional $409,426 in grant funding from the National Multiple Sclerosis Society.

28 Mar 2011

University of Aberdeen, TPP enter agreement to develop novel future medicines

TPP Global Development Ltd has announced an agreement with the University of Aberdeen to collaborate on the development of novel pre-clinical intellectual property originated within the University.

28 Mar 2011

AACR to honor UNC scientist with $181,000 grant for breast cancer research

The American Association for Cancer Research announced today that Carey Anders, MD, assistant professor of medicine and a member of UNC Lineberger Comprehensive Cancer Center will receive a Breast Cancer Research Foundation-AACR Grant for Translational Breast Cancer Research. The $181,000 grant will be presented at the organization's 102nd Annual Meeting, to be held in Orlando, Florida, April 2-6.

28 Mar 2011

Major breakthrough in brain signal processing

A team of Neuroscientists from NeuroCure Cluster of Excellence at Charité - Universitätsmedizin Berlin and Baylor College of Medicine in Houston, Texas, have made a major breakthrough in understanding how signals are processed in the human brain.

28 Mar 2011

Study identifies unique adult animal stem cells that can turn into neurons

A group of scientists at Marshall University is conducting research that may someday lead to new treatments for repair of the central nervous system.

25 Mar 2011

Quantum dots allow stem cell therapy monitoring for brain injury

A new technique using "quantum dots" produced through nanotechnology is a promising approach to monitoring the effects of stem cell therapies for stroke and other types of brain damage, reports the April issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

25 Mar 2011

Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has enrolled 33 percent of the total projected patients required for its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).

24 Mar 2011

Central Nervous System News and Research

SMT announces $10.5 million financing to develop novel device for use in TAVI procedures

ACADIA extends collaboration agreement with Allergan for drug discovery platform

Researchers study role of acetylation in Alzheimer's disease

Invida, Roche partner to commercialize primary care products

Omeros announces outcome from OMS103HP Phase 3 study in patients undergoing ACL surgery

Sleep apnea along with excessive daytime sleepiness elevates risk of death in older adults

New research sheds light on Sudden Infant Death Syndrome

AAN honors Mayo Clinic researcher with John Dystel Prize for MS work

Vanda to initiate tasimelteon Phase IIb/III clinical trial in Major Depressive Disorder

Adeona reports $3,164,512 net revenue for 2010

Rexahn's RX-5902 pre-clinical data against cancer to be presented at AACR Annual Meeting

Tips on neurobiology of learning

Atypical antipsychotics is a safe mental health medication for nursing home residents

NMSS grants Adeona's ongoing Trimesta trial with $409,426 to treat MS

University of Aberdeen, TPP enter agreement to develop novel future medicines

AACR to honor UNC scientist with $181,000 grant for breast cancer research

Major breakthrough in brain signal processing

Study identifies unique adult animal stem cells that can turn into neurons

Quantum dots allow stem cell therapy monitoring for brain injury

Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News